Related Experiment Video
Updated: May 28, 2026

Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
Antiplatelet agents for the treatment and prevention of atherothrombosis
Carlo Patrono1, Felicita Andreotti, Harald Arnesen
1Department of Pharmacology, Catholic University School of Medicine, Rome, Italy. carlo.patrono@rm.unicatt.it
Insights
This review provides updated guidance on antiplatelet drug strategies for preventing and treating atherothrombosis. It aims to help physicians select optimal antiplatelet therapy for individual patients based on risk and clinical presentation.
Area of Science:
- Cardiology
- Pharmacology
- Thrombosis Research
Background:
- Previous reviews by the European Society of Cardiology (ESC) and American College of Chest Physicians (ACCP) have addressed antiplatelet drug clinical pharmacology.
- Collaborative meta-analyses of 287 secondary and 6 primary prevention trials offer insights into antiplatelet drug efficacy and safety in atherothrombosis.
Purpose of the Study:
- To provide an updated instrument for practicing physicians.
- To guide the selection of optimal antiplatelet strategies for individual patients.
- To address patients at risk or with clinical manifestations of atherothrombosis.
Main Methods:
- Review of existing clinical pharmacology data on antiplatelet drugs.
- Synthesis of evidence from meta-analyses of primary and secondary prevention trials.
- Development of updated clinical guidance for physicians.
Main Results:
- The document consolidates information on antiplatelet drug efficacy and safety.
- It offers a framework for tailoring antiplatelet therapy.
- It addresses the complexities of managing atherothrombosis.
Conclusions:
- An updated antiplatelet strategy is crucial for managing patients with atherothrombosis.
- Physician guidance is essential for selecting appropriate antiplatelet therapy.
- Individualized treatment based on patient risk and presentation is recommended.
Abstract:
The clinical pharmacology of antiplatelet drugs has been reviewed previously by the European Society of Cardiology (ESC) Task force and by the 8th American College of Chest Physicians (ACCP) Evidence-Based Clinical Practice Guidelines. Moreover, information on the efficacy and safety of antiplatelet drugs in the treatment and prevention of atherothrombosis is provided by collaborative meta-analyses of 287 secondary prevention trials and 6 primary prevention trials. The present document intends to provide practicing physicians with an updated instrument to guide their choice of the most suitable antiplatelet strategy for the individual patient at risk, or with different clinical manifestations, of atherothrombosis.
Related Concept Videos
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Peripheral Artery Disease III: Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Atherosclerosis III: Management
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Coronary Artery Disease V: Interprofessional Care
